Navigation Links
Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
Date:11/26/2008

VEDBAEK, Denmark, November 26 /PRNewswire-FirstCall/ -- Exiqon A/S, traded at the NASDAQ OMX Copenhagen ("EXQ"), reports continued strong growth in research product sales during the third quarter of 2008. Revenues were positively affected by the execution of a license agreement with Roche Diagnostics for use of Exiqon's LNA(TM) technology. Initial fourth quarter sales were negatively affected by supply of arrays that failed Exiqon's internal quality tests causing a slow down in executed sales orders. Although the supply problems have now been addressed, Exiqon revises its 2008 total year guidance of revenue of DKK 140-150 million to now DKK 120-130 million. As a result, a net loss of DKK 115-125 is now anticipated compared to previous expectations of a net loss of DKK 100-115 million.

    - Revenue in the third quarter of 2008 increased five fold on the
      year-earlier period to DKK 51.3 million, totaling DKK 95.8 million in
      the first nine months of 2008.

    - Compared third quarter last year product sales increased by 329% to DKK
      28 million totaling DKK 68,5 million in the first nine months of 2008.
      Research product sales grew organically by 141%.

    - Net loss for the third quarter of 2008 was DKK 10.1 million totaling
      DKK 73.6 million in the first nine months of 2008. EPS amounted to DKK
      -0.35 in the third quarter of 2008 and DKK -2.55 in the first nine
      months of 2008.

    - License granted to Roche Diagnostics for use of Exiqon's proprietary
      LNA(TM) detection technology in a new product line for RealTime ready
      qPCR assays demonstrates the value of LNA(TM) as a detection
      technology.

    - The integration of former Oncotech Inc - now Exiqon Diagnostics Inc -
      remains on track for the first miRNA diagnostic product launch to be
      announced in December 2008.

Lars Kongsbak, President and CEO says: "Product demand remains stron
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
2. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
3. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
4. Misonix Announces Interim Distribution Agreement for Italy
5. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
6. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
7. Arpida Reports Interim Results for Six Months to 30 June 2008
8. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
9. LPBP Inc. - Re-filing certification of interim filings
10. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MX (PRWEB) September 18, 2014 September ... Mexico City, MX. ASEA is the manufacturer of the ... the skin care product, RENU28. , The Mexico ... Vice President Duvan Botero, and ASEA Field Leader Shawn ... holds a PhD in Atomic/Medical Physics from the University ...
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... September 17, 2014 A biodegradable ... microorganisms such as bacteria, fungi, and algae into ... methane, biomass, inorganic compounds, carbon dioxide, and humus ... customer base and improved costs, biodegradable polymers are ... viable alternative to conventional polymers. Primary factors that ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... Receive Funding, From Allied Minds to Commercialize Novel Technology for the ... ... Aliquots, BOSTON, July 2 Allied Minds, a pre-seed investment,corporation ... Development, and Northeastern,University announce the creation of CryoXtract Instruments, LLC, a ...
... levels as a possible ... predictor of clinical activity -, TORONTO, ... ("Lorus" or the "Corporation"), a biopharmaceutical company,specializing in the research ... cancer, today announced publication by,an Ohio State University (OSU) clinical ...
... Microfluidic Systems Inc.,(MFSI) announced today that it has ... of Microfluidic - Bioagent Autonomous Networked Detector,(M-BAND). This ... funded phases by the DHS,Science and Technology Directorate ... allow for low-volume production of automated,systems for extended ...
Cached Biology Technology:Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 2Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 3
(Date:9/17/2014)... 2014) A rare genetic disorder known as Jacobsen syndrome ... joint investigation by researchers at San Diego State University ... to suggesting better treatment options for people with Jacobsen ... genetic underpinnings of autism., Jacobsen syndrome affects approximately 1 ... Health. It occurs in a person when there is ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute ... genes differentially expressed in normal accompanying cells in ... used to classify colorectal tumors, predict the evolution ... decisions to prevent relapses. , Biomarkers ... in our population considering both sexes. About 30,000 ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2
... how fish have evolved over the last 400 million ... A research team led by Dr Michael Berenbrink, a ... revealed how modern fish, such as pike and cod, ... levels using a gas-filled swimbladder. , Dr Berenbrink investigated ...
... have "programmed" cells to make their own contrast agents, ... results, appearing in the April issue of Nature Medicine, ... emerging field of molecular therapeutics and for monitoring the ... years it has been the chemist's job to develop ...
... better than others? Scientists at Cardiff University, in collaboration ... of stickleback fish - have identified the chemical responsible. ... that males with body odour that is particularly attractive ... , To prove this, the researchers produced a synthetic ...
Cached Biology News:Scientists discover how fish evolved to float at different sea depths 2Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals 2Love at first smell 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: